Sectors
DMRA
Damora Therapeutics, Inc.
29.27
1 x 28.66
1 x 46.55
bid
ask
-
0.27
0.91%
09:37 AM
timesize
| Ytd | 27.21% | |
| 1y | 765.98% |
29.11
day range
30.39
2.58
52 week range
34.14
| Open | 29.89 | Prev Close | 29.54 | Low | 29.11 | High | 30.39 | Mkt Cap | 1.79B |
| Vol | 9.18K | Avg Vol | 585.31K | EPS | -8.82 | P/E | -3.30 | Forward P/E | -14.40 |
| Beta | 1.47 | Short Ratio | 4.84 | Inst. Own | 102.22% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 26.52 | 200-d Avg | 24.35 | 1yr Est | 44.67 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-10-30 | 2026-09 | -0.45 | N/A | N/A | N/A |
| 2026-08-10 | 2026-06 | -0.4 | -0.39 | 0.01 | 2.85% |
| 2026-05-12 | 2026-03 | -0.21 | -0.62 | -0.41 | -195.24% |
| 2026-03-18 | 2025-12 | -0.14 | -3.24 | -3.1 | -2216.35% |
| 2025-11-06 | 2025-09 | -0.1 | -2.36 | -2.26 | -2337.76% |
| 2025-08-05 | 2025-06 | 0 | -2.6 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-30 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-07-27 | Jefferies | Upgrade | Buy | |
| 2026-07-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-06-12 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-06-11 | HC Wainwright & Co. | Upgrade | Buy | |
| 2026-05-28 | Wedbush | Upgrade | Outperform |
Profile
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-08 | BRUNO JULIANNE | Director | 137.03K | Conversion of Exercise of derivative security |
| 2026-02-08 | FAIRMOUNT FUNDS MANAGEMENT LLC | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2026-01-01 | FIRMANI LORI | Chief Financial Officer | 931.00 | Sale |
| 2026-01-04 | HEWES LEMUEL BECKER | Officer | 264.63K | Stock Award(Grant) |
| 2026-03-29 | JARRETT A JENNIFER | Chief Executive Officer | 500.00K | Stock Award(Grant) |
| 2026-01-04 | SATTARZADEH SHERWIN | Chief Operating Officer | 190.38K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Rothschild Investment LLC | 34.00 | 1.00K | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.83M | 54.03M | 2.97% |
| 2026-04-29 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 834.04K | 24.64M | 1.35% |
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 712.29K | 21.04M | 1.16% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 535.39K | 15.82M | 0.87% |
| 2026-05-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 500.00K | 14.77M | 0.81% |
| 2026-05-30 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 454.56K | 13.43M | 0.74% |